Precigen (PGEN) Receivables (2012 - 2026)
Precigen (PGEN) reported Receivables of $26.7 million for Q1 2026, up 2409.87% year-over-year from $1.1 million in Q1 2025, and up 512.22% quarter-over-quarter from $4.4 million in Q4 2025.
Precigen (PGEN) Receivables (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Receivables data on file, last reported at $26.7 million in Q1 2026.
- Receivables for Q1 2026 came in at $26.7 million, up 2409.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $26.7 million (up 2409.87% YoY), and the FY2025 annual result was $4.4 million, up 275.06% from the prior year.
- Receivables grew to $26.7 million in Q1 2026 per PGEN's latest filing, from $4.4 million in the prior quarter.
- Over five years, Receivables peaked at $26.7 million in Q1 2026 and troughed at $479000.0 in Q3 2024.
- A 5-year average of $7.2 million and a median of $1.6 million in 2023 frame the typical range for Receivables.
- The sharpest annual moves came in 2024 and 2026: Receivables plunged 96.47% in 2024, then surged 2409.87% in 2026.
- A 5-year view of Receivables shows it stood at $13.4 million in 2022, then plunged by 88.24% to $1.6 million in 2023, then declined by 26.16% to $1.2 million in 2024, then jumped by 275.06% to $4.4 million in 2025, then surged by 512.22% to $26.7 million in 2026.
- Business Quant data shows PGEN's Receivables at $26.7 million in Q1 2026, $4.4 million in Q4 2025, and $1.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn | 26.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.71 Mn |
| Dec 31, 2025 | 4.36 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 571,000.00 |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | 1.16 Mn |
| Sep 30, 2024 | 479,000.00 |
| Jun 30, 2024 | 511,000.00 |
| Mar 31, 2024 | 872,000.00 |
| Dec 31, 2023 | 1.58 Mn |
| Sep 30, 2023 | 13.58 Mn |
| Jun 30, 2023 | 14.41 Mn |
| Mar 31, 2023 | 14.30 Mn |
| Dec 31, 2022 | 13.39 Mn |
| Sep 30, 2022 | 2.44 Mn |
| Jun 30, 2022 | 1.33 Mn |
| Mar 31, 2022 | 24.85 Mn |
| Dec 31, 2021 | 1.91 Mn |
| Sep 30, 2021 | 20.24 Mn |
| Jun 30, 2021 | 26.04 Mn |